Evoke Pharma, Inc. (EVOK) Stock

About Evoke Pharma, Inc.

Evoke Pharma, Inc. operates as a specialized pharmaceutical entity, primarily focused on inventing and bringing to market therapeutic agents for various digestive system illnesses. The company's lead development candidate is Gimoti, a metoclopramide nasal spray, which has progressed through and completed its Phase 3 clinical trials. This medicine is being developed to mitigate symptoms associated with both acute and recurring diabetic gastroparesis, specifically in female patients. Evoke Pharma distributes its offerings to a broad base of healthcare professionals, encompassing digestive disease specialists, internists, general practitioners, and certain other medical providers. Established in 2007, the company's corporate offices are situated in Solana Beach, California.

Evoke Pharma, Inc. is headquartered in US.

Evoke Pharma, Inc. (EVOK) stock trades at $11.00 with a market capitalization of $18.95M. The stock is valued at a price-to-earnings (P/E) ratio of -6.96, price-to-book of 8.37, price-to-sales of 1.70. Over the past 52 weeks the stock has ranged between $1.94 and $11.00, and currently trades at its 52-week high.

On profitability, Evoke Pharma, Inc. generates a return on equity (ROE) of -89.12%, return on capital employed of -117.30%, an operating margin of -35.97%, a net profit margin of -36.28%.

Official website: www.evokepharma.com